Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- daunorubicin
- Mayzent (siponimod)
Interactions between your drugs
DAUNOrubicin siponimod
Applies to: daunorubicin, Mayzent (siponimod)
Before starting siponimod, let your doctor know if you are currently receiving treatment with DAUNOrubicin. Using siponimod in this situation can increase the risk of an irregular heart rhythm that may be serious or life-threatening. This is most likely to occur within 5 to 6 days after starting treatment with siponimod. Talk to your doctor if you are uncertain whether you should be treated with these medications at the same time. Contact your doctor if you develop dizziness, lightheadedness, fainting, shortness of breath, chest pain, or heart palpitations during treatment.
Combining these medications can also increase the risk of serious infections. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Because siponimod can remain in your blood after the last dose, interactions with other drugs may occur for some time even after you have stopped taking it. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Trexall
Trexall is used for acute lymphoblastic leukemia, acute lymphocytic leukemia, breast cancer ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.